Skip to main content

PLATAFORMAS NANOPLASMONICAS POINT-OF-CARE COMO SISTEMA INNOVADOR DE DIAGNOSTICO Y SEGUIMIENTO DE TERAPIAS

TEC2016-78515-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2016
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIÓ INSTITUT CATALÀ DE NANOCIÈNCIA I NANOTECNOLOGIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 19
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A label-free nanostructured plasmonic biosensor based on Blu-ray discs with integrated microfluidics for sensitive biodetection

  • López-Muñoz, Gerardo A.
  • Estévez, M. Carmen
  • Peláez-Gutierrez, E. Cristina
  • Homs-Corbera, Antoni
  • García-Hernández, Mar
  • Imabaud, J. Ignacio
  • Lechuga, Laura M.
Nanostructure-based plasmonic biosensors have quickly positioned themselves as interesting candidates for the design of portable optical biosensor platforms considering the potential benefits they can offer in integration, miniaturization, multiplexing, and real-time label-free detection. We have developed a simple integrated nanoplasmonic sensor taking advantage of the periodic nanostructured array of commercial Blu-ray discs. Sensors with two gold film thicknesses (50 and 100 nm) were fabricated and optically characterized by varying the oblique-angle of the incident light in optical reflectance measurements. Contrary to the use normal light incidence previously reported with other optical discs, we observed an enhancement in sensitivity and a narrowing of the resonant linewidths as the light incidence angle was increased, which could be related to the generation of Fano resonant modes. The new sensors achieve a figure of merit (FOM) up to 35 RIU and a competitive bulk limit of detection (LOD) of 6.3×10 RIU. These values significantly improve previously reported results obtained with normal light incidence reflectance measurements using similar structures. The sensor has been combined with versatile, simple, ease to-fabricate microfluidics. The integrated chip is only 1 cm (including a PDMS flow cell with a 50 µm height microfluidic channel fabricated with double-sided adhesive tape) and all the optical components are mounted on a 10 cm×10 cm portable prototype, illustrating its facile miniaturization, integration and potential portability. Finally, to assess the label-free biosensing capability of the new sensor, we have evaluated the presence of specific antibodies against the GTF2b protein, a tumor-associate antigen (TAA) related to colorectal cancer. We have achieved a LOD in the pM order and have assessed the feasibility of directly measuring biological samples such as human serum., GL acknowledges financial support from CONACYT 225362 scholarship. We acknowledge the financial support from COLONTEST project (RETOS-COLABORACIÓN Subprogram, RTC-2014-1518-1) and from PreDICT project (Programa estatal de investigación, desarrollo e innovación orientada a los Retos de la Sociedad, TEC2016-78515-R). The NanoB2A is a consolidated research group (Grup de Recerca) of the Generalitat de Catalunya and has support from the Departament d’Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (2014 SGR 624). ICN2 is the recipient of Grant SEV-2013-0295 from the “Severo Ochoa Centers of Excellence” Program of Spanish MINECO. The authors thank Miguel Berenguel Alonso and Prof. Julián Alonso Chamarro from the Group of Sensors and Biosensors (Department of Chemistry, Autonomous University of Barcelona) for their technical support in this work., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Gold/silver/gold trilayer films on nanostructured polycarbonate substrates for direct and label‐free nanoplasmonic biosensing

  • López-Muñoz, Gerardo A.
  • Estévez, M. Carmen
  • Vázquez-García, Marc
  • Berenguel-Alonso, Miguel
  • Alonso-Chamarro, Julián
  • Lechuga, Laura M.
Ultrasmooth gold/silver/gold trilayer nanostructured plasmonic sensors were obtained using commercial Blu-ray optical discs as nanoslits-based flexible polymer substrates. A thin gold film was used as an adhesion and nucleation layer to improve the chemical stability and reduce the surface roughness of the overlying silver film, without increasing ohmic plasmon losses. The structures were physically and optically characterized and compared with nanostructures of single gold layer. Ultrasmooth and chemically stable trilayer nanostructures with a surface roughness <0.5 nm were obtained following a simple and reproducible fabrication process. They showed a figure of merit (FOM) value up to 69.2 RIU-1 which is significantly higher (more than 95%) than the gold monolayer counterpart. Their potential for biosensing was demonstrated by employing the trilayer sensor for the direct and refractometric (label-free) detection of C-reactive protein (CRP) biomarker in undiluted urine achieving a Limit of Detection (LOD) in the pM order., Departament d'Universitats, Recerca i Societat de la Informació, Grant/Award Number: 2014 SGR 624; Ministerio de Economía y Competitividad, Grant/Award Number: SEV-2013-0295; Programa Estatal de investigación, desarrollo e innovación orientada a los Retos de la Sociedad, Grant/Award Number: TEC2016-78515-R; Spanish Ministry of Economy, Industry and Competitiveness (MINECO, Grant/Award Number: SEV2013-0295; CERCA programme/Generalitat de Catalunya; Departament d'Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya, Grant/Award Number: 2014 SGR 624; PreDICT project, Grant/Award Number: TEC2016-78515-R; CONACYT, Grant/Award Number: 225362, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Advanced evanescent-wave optical biosensors for the detection of nucleic acids: An analytic perspective

  • Huertas, César S.
  • Calvo-Lozano, Olalla
  • Mitchell, Arnan
  • Lechuga, Laura M.
Evanescent-wave optical biosensors have become an attractive alternative for the screening of nucleic acids in the clinical context. They possess highly sensitive transducers able to perform detection of a wide range of nucleic acid-based biomarkers without the need of any label or marker. These optical biosensor platforms are very versatile, allowing the incorporation of an almost limitless range of biorecognition probes precisely and robustly adhered to the sensor surface by covalent surface chemistry approaches. In addition, their application can be further enhanced by their combination with different processes, thanks to their integration with complex and automated microfluidic systems, facilitating the development of multiplexed and user-friendly platforms. The objective of this work is to provide a comprehensive synopsis of cutting-edge analytical strategies based on these label-free optical biosensors able to deal with the drawbacks related to DNA and RNA detection, from single point mutations assays and epigenetic alterations, to bacterial infections. Several plasmonic and silicon photonic-based biosensors are described together with their most recent applications in this area. We also identify and analyse the main challenges faced when attempting to harness this technology and how several innovative approaches introduced in the last years manage those issues, including the use of new biorecognition probes, surface functionalization approaches, signal amplification and enhancement strategies, as well as, sophisticated microfluidic solutions., CH was a recipient of an RMIT Vice Chancellor's Postdoctoral Fellowship. The ICN2 was funded by the CERCA program/Generalitat de Catalunya. ICN2 was supported by the Severo Ochoa Centres of Excellence program funded by the Spanish Research Agency (AEI, grant no. SEV-2017-0706). ICN2 and the authors acknowledge the support of the Spanish MINECO, the Spanish Research Agency and the European Social Fund (ESF) for the grant for predoctoral contracts in the Subprograma Estatal de Formación del Programa Estatal de Promoción del Talento y su Empleabilidad (ref. BES-2017-080527) linked to the TEC 2016-78515-R project., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Boosting cancer immunotherapies with optical biosensor nanotechnologies

  • Soler, María
  • Lechuga, Laura M.
An increasing number of cancer patients have found new hope in the form of recently discovered cell immunotherapies. These novel treatments empower our own immune system to fight and eradicate the malignant tumours, even in metastatic stages. Unprecedented outcomes have been demonstrated with bioengineered cells especially modified in laboratories to trigger a highly specific and active anti-tumour function; however, a main bottleneck for the implementation of these promising therapies resides in the old-fashioned and limited techniques employed for the in vitroanalysis and study of cells during manufacturing and testing processes. Optical label-free biosensors are currently arising as promising analytical technologies for a simplified and accurate cell analysis. In particular, biosensors based on evanescent field principles enable direct, non-invasive, and real-time monitoring of biological events, showing outstanding sensitivities and excellent robustness. Furthermore, these biosensors are easily incorporated in lab-on-a-chip platforms for simple operation and implementation in clinical laboratories. In this review, the authors present and discuss the more recent research aimed to develop label-free optical biosensors for the analysis of live cells and the direct benefits offered to cell immunotherapy production allowing for its widespread implementation., The authors acknowledge the financial support from PreDICT project (Programa estatal de investigación, desarrollo e innovación orientada a los Retos de la Sociedad, TEC2016-78515-R). ICN2 is the recipient of Grant SEV-2017-0706 from the “Severo Ochoa Centers of Excellence” Program of Spanish Ministry of Science., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Fast and Accurate Pneumocystis Pneumonia Diagnosis in Human Samples Using a Label-Free Plasmonic Biosensor

  • Calvo-Lozano, Olalla
  • Aviñó, Anna
  • Friaza Patiño, Vicente
  • Medina-Escuela, Alfonso
  • Huertas, César S.
  • Calderón, Enrique J.
  • Eritja Casadellà, Ramón
  • Lechuga, Laura M.
© 2020 by the authors., Pneumocystis jirovecii is a fungus responsible for human Pneumocystis pneumonia, one of the most severe infections encountered in immunodepressed individuals. The diagnosis of Pneumocystis pneumonia continues to be challenging due to the absence of specific symptoms in infected patients. Moreover, the standard diagnostic method employed for its diagnosis involves mainly PCR-based techniques, which besides being highly specific and sensitive, require specialized personnel and equipment and are time-consuming. Our aim is to demonstrate an optical biosensor methodology based on surface plasmon resonance to perform such diagnostics in an efficient and decentralized scheme. The biosensor methodology employs poly-purine reverse-Hoogsteen hairpin probes for the detection of the mitochondrial large subunit ribosomal RNA (mtLSU rRNA) gene, related to P. jirovecii detection. The biosensor device performs a real-time and label-free identification of the mtLSU rRNA gene with excellent selectivity and reproducibility, achieving limits of detection of around 2.11 nM. A preliminary evaluation of clinical samples showed rapid, label-free and specific identification of P. jirovecii in human lung fluids such as bronchoalveolar lavages or nasopharyngeal aspirates. These results offer a door for the future deployment of a sensitive diagnostic tool for fast, direct and selective detection of Pneumocystis pneumonia disease., The ICN2 is funded by the CERCA program/Generalitat de Catalunya. The ICN2 was supported by the Severo Ochoa Centres of Excellence program funded by the Spanish Research Agency (AEI, grant no. SEV-2017-0706). The ICN2 and O.C.L. acknowledge the economic support of the Spanish MINECO, the Spanish Research Agency and the European Social Fund (ESF) for the grant for predoctoral contracts in the Subprograma Estatal de Formación del Programa Estatal de Promoción del Talento y su Empleabilidad (ref. BES-2017-080527) linked to the TEC 2016-78515-R project PREDICT. Dr C.S.H. is a recipient of an RMIT Vice Chancellor’s Postdoctoral Fellowship. This study was supported, in part, by the Red Iberoamericana sobre Pneumocystosis in the framework of The Ibero-American Programme for Science, Technology and Development (grant CYTED 212RT0450). Financial support was also provided by the Spanish Ministerio de Ciencia e Innovación (MICINN) (Projects CTQ2017-84415-R)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Site-specific mRNA cleavage for selective and quantitative profiling of alternative splicing with label-free optical biosensors

  • Huertas, César S.
  • Bonnal, Sophie
  • Soler, María
  • Escuela, Alfonso M.
  • Valcárcel, Juan
  • Lechuga, Laura M.
Alternative splicing of mRNA precursors is a key process in gene regulation, contributing to the diversity of proteomes by the alternative selection of exonic sequences. Alterations in this mechanism are associated with most cancers, enhancing their proliferation and survival, and can be employed as cancer biomarkers. Label-free optical biosensors are ideal tools for the highly sensitive and label-free analysis of nucleic acids. However, their application for alternative splicing analysis has been hampered due to the formation of complex and intricate long-range base-pairing interactions which make the direct detection in mRNA isoforms difficult. To solve this bottleneck, we introduce a methodology for the generation of length-controlled RNA fragments from purified total RNA, which can be easily detected by the biosensor. The methodology seizes RNase H enzyme activity to degrade the upstream and downstream RNA segments flanking the target sequence upon hybridization to specific DNA oligos. It allows the fast and direct monitoring of Fas gene alternative splicing in real time, employing a surface plasmon resonance biosensor. We demonstrate the selective and specific detection of mRNA fragments in the pM–nM concentration range, reducing quantification errors and showing 81% accuracy when compared to RT-qPCR. The site-specific cleavage outperformed random RNA hydrolysis by increasing the detection accuracy by 20%, making this methodology particularly appropriate for label-free quantification of alternative splicing events in complex samples., We acknowledge financial support from the PreDICT project (Programa estatal de investigacion, desarrollo e innovacion orientada a los Retos de la Sociedad, Grant TEC2016-78515-R). SPR studies were performed at the ICTS NANBIOSIS, specifically at the Biodeposition and Biodetection Unit (http://www.nanbiosis.es/portfolio/u4-biodeposition-andbiodetection-unit/). ICN2 is the recipient of Grant SEV-2017-0706 from the “Severo Ochoa Centers of Excellence” Program of Spanish Ministry of Science. Work in the J.V. laboratory is supported by the European Research Council (Grant ERC AdvG 670146), AGAUR, Spanish Ministry of Economy and Competitiveness (Grants BFU 2014-005153 and BFU 2017 89308-P), and the Centre of Excellence Severo Ochoa. C.S.H. is a recipient of an RMIT Vice Chancellor’s Postdoctoral Fellowship., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Label-free plasmonic biosensor for rapid, quantitative, and highly sensitive COVID-19 serology: implementation and clinical validation

  • Calvo-Lozano, Olalla
  • Sierra, Miquel
  • Soler, María
  • Estévez, M. Carmen
  • Chiscano- Camón, Luis
  • Ruiz-Sanmartín, Adolfo
  • Ruiz-Rodriguez, Juan Carlos
  • Ferrer, Ricard
  • González-López, Juan José
  • Esperalba, Juliana
  • Fernández-Nava, Candela
  • Bueno, Leticia
  • López-Aladid, Rubén
  • Torres, Antoni
  • Fernández-Barat, Laia
  • Attoumani, Sarah
  • Charrel, Remi
  • Coutard, Bruno
  • Lechuga, Laura M.
Serological tests are essential for the control and management of COVID-19 pandemic, not only for current and historical diagnostics but especially for surveillance, epidemiological, and acquired immunity studies. Clinical COVID-19 serology is routinely performed by enzymatic or chemiluminescence immunoassays (i.e., ELISA or CLIA), which provide good sensitivities at the expense of relatively long turnaround times and specialized laboratory settings. Rapid serological tests, based on lateral flow assays, have also been developed and widely commercialized, but they suffer from limited reliability due to relatively low sensitivity and specificity. We have developed and validated a direct serological biosensor assay employing proprietary technology based on Surface Plasmon Resonance (SPR). The biosensor offers a rapid -less than 15 min- identification and quantification of SARS-CoV-2 antibodies directly in clinical samples, without the need of any signal amplification. The portable plasmonic biosensor device employs a custom-designed multi-antigen sensor biochip, combining the two main viral antigens (RBD peptide and N protein), for simultaneous detection of human antibodies targeting both antigens. The SPR serology assay reaches detection limits in the low ng mL-1 range employing polyclonal antibodies as standard, which are well below the commonly detected antibody levels in COVID-19 patients. The assay has also been implemented employing the first WHO approved anti-SARS-CoV-2 immunoglobulin standard. We have carried out a clinical validation with COVID-19 positive and negative samples (n=120) that demonstrates the excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor device as an accurate, robust, and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the management of COVID-19 patients and for the evaluation of immunological status during vaccination, treatment or in front of emerging variants., H2020 Research and Innovation Programme of the European Commission Project, No. 101003544 Spanish Research Agency (AEI, grant no. SEV-2017-0706AEI, grant no. SEV-2017-0706) Spanish Ministry of Science and Innovation and the Spanish Research Agency and the European Social Fund (ESF)BES-2017-080527 GENCAT-DGRIS COVID EU H2020 Programme (644956) Plan Nacional de I+D+i 2013-2016 ISCIII- Ministerio de Ciencia e Innovación, Vall d’Hebron University Hospital Biobank PT17/0015/0047 European Virus Archive GLOBAL (EVA-GLOBAL) EU Horizon 2020 (grant agreement No. 871029) Fundació Glòria Soler for COVIDBANK collection Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003), No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology: Implementation and Clinical Validation

  • Calvo-Lozano, Olalla
  • Sierra, Miquel
  • Soler, María
  • Estévez, M. Carmen
  • Chiscano- Camón, Luis
  • Ruiz-Sanmartín, Adolfo
  • Ruiz-Rodriguez, Juan Carlos
  • Ferrer, Ricard
  • González-López, Juan José
  • Esperalba, Juliana
  • Fernández-Nava, Candela
  • Bueno, Leticia
  • López-Aladid, Rubén
  • Torres, Antoni
  • Fernández-Barat, Laia
  • Attoumani, Sarah
  • Charrel, Remi
  • Coutard, Bruno
  • Lechuga, Laura M.
Serological tests are essential for the control and management of COVID-19 pandemic (diagnostics and surveillance, and epidemiological and immunity studies). We introduce a direct serological biosensor assay employing proprietary technology based on plasmonics, which offers rapid (<15 min) identification and quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in clinical samples, without signal amplification. The portable plasmonic device employs a custom-designed multiantigen (RBD peptide and N protein) sensor biochip and reaches detection limits in the low ng mL–1 range employing polyclonal antibodies. It has also been implemented employing the WHO-approved anti-SARS-CoV-2 immunoglobulin standard. A clinical validation with COVID-19 positive and negative samples (n = 120) demonstrates its excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor as an accurate and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the disease management and for the evaluation of immunological status during vaccination or treatment., ICN2 and UVE acknowledge financial support from H2020 Research and Innovation Programme of the European Commission (H202-SC1-PHE-Coronavirus-2020, CONVAT Project, No. 101003544). The ICN2 is funded by the CERCA program/Generalitat de Catalunya and supported by the Severo Ochoa Centres of Excellence program funded by the Spanish Research Agency (AEI, grant no. SEV-2017-0706). ICN2 group is very grateful to EPI Industries (Barcelona, Spain) for its kind donation supporting our research in COVID-19. O.C.-L. acknowledges the economic support from the Spanish Ministry of Science and Innovation and the Spanish Research Agency and the European Social Fund (ESF) (ref. BES-2017-080527) linked to the TEC 2016-78515-R project Predict. A part of the work was supported by the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the EU Horizon 2020 (grant agreement No. 871029). A.T. and L.F.-B. acknowledge financial support from GENCAT-DGRIS COVID. We are indebted to all the patients who accepted to participate contributing to science advancement. We are indebted to the HCB-IDIBAPS Biobank for the human samples and data procurement and to the Fundació Glòria Soler for its support to the COVIDBANK collection. We thank the IDIBAPS Biobank for its valuable contribution to sample processing and storage. The authors acknowledge the EU Horizon 2020 Program under grant agreement no. 644956 (RAIS project) for funding the Hospital Vall d’Hebron Biobank. The VHIR-HUVH is supported by Plan Nacional de I + D + i 2013-2016 and ISCIII-Ministerio de Ciencia e Innovación, and Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003)─cofinanced by European Development Regional Fund “A way to achieve Europe,” Operative program Intelligent Growth 2014. Part of the samples and data from patients included in this study were provided by the Vall d’Hebron University Hospital Biobank (PT17/0015/0047), integrated in the Spanish National Biobanks Network, and they were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committee. The authors kindly appreciate the generous donation of samples and clinical data of the donors of the Sepsis Bank of HUVH Biobank and COVID-19 patients attended at HUVH., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

One-step and real-time detection of microRNA-21 in human samples for lung cancer biosensing diagnosis

  • Calvo-Lozano, Olalla
  • García-Aparicio, Pablo
  • Raduly, Lajos-Zsolt
  • Estévez, M. Carmen
  • Berindan-Neagoe, Ioana
  • Ferracin, Manuela
  • Lechuga, Laura M.
The rapid diagnosis of cancer, especially in its early stages, is crucial for on-time medical treatment and for increasing the patient survival rate. Lung cancer shows the highest mortality rate and the lowest 5-year survival rate due to the late diagnosis in advanced cancer stages. Providing rapid and reliable diagnostic tools is a top priority to address the problem of a delayed cancer diagnosis. We introduce a nanophotonic biosensor for the direct and real-time detection in human plasma of the microRNA-21-5p biomarker related to lung cancer. The biosensor employs a silicon photonic bimodal interferometric waveguide that provides a highly sensitive detection in a label-free format. We demonstrate a very competitive detectability for direct microRNA-21-5p biomarker assays in human plasma samples (estimated LOD: 25 pM). The diagnostic capability of our biosensor was validated by analyzing 40 clinical samples from healthy individuals and lung cancer patients, previously analyzed by reverse-transcription quantitative polymerase chain reaction (qRT-PCR). We could successfully identify and quantify the levels of microRNA in a one-step assay, without the need for DNA extraction or amplification steps. The study confirmed the significance of implementing this biosensor technique compared to the benchmarking molecular analysis and showed excellent agreement with previous results employing the traditional qRT-PCR. This work opens new possibilities for the true implementation of point-of-care biosensors that enable fast, simple, and efficient early diagnosis of cancer diseases., The ICN2 acknowledges the financial support from the Spanish Research Agency (AEI), Ministry of Science, Innovation, and Universities through the PREDICT (TEC2016-78515-R) and EROICA PID2019-105132RB-I00) projects. ICN2 is funded by the CERCA Program/Generalitat de Catalunya and supported by the Severo Ochoa Centres of Excellence program funded by the Spanish Research Agency (AEI, grant no. SEV-2017-0706). O.C-L. acknowledges the economic support from the Spanish Ministry of Science and Innovation and the Spanish Research Agency and the European Social Fund (ESF) (ref. BES-2017-080527) linked to the PREDICT project. Research Center for Functional Genomics, Biomedicine and Translational Medicine acknowledges “Clinical and economic impact of personalized targeted anti-microRNA therapies in reconverting lung cancer chemoresistance”, CANTEMIR, no. POC-P_37_796/2016. This work was supported by the FLAG-ERA grant LEGOCHIP, funded by the Italian National Research Council and the Spanish National Research Agency (PCI2019-111890-2)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Gold/silver/gold trilayer films on nanostructured polycarbonate substrates for direct and label-free nanoplasmonic biosensing

  • López Muñoz, Gerardo Arturo
  • Estévez, M. Carmen|||0000-0003-3694-7186
  • Vázquez García, Marc
  • Berenguel-Alonso, Miguel|||0000-0002-3759-3634
  • Alonso-Chamarro, Julián|||0000-0002-6804-6027
  • Homs Corbera, Antoni
  • Lechuga, Laura M.|||0000-0001-5187-5358
Ultrasmooth gold/silver/gold trilayer nanostructured plasmonic sensors were obtained using commercial Blu-ray optical discs as nanoslits-based flexible polymer substrates. A thin gold film was used as an adhesion and nucleation layer to improve the chemical stability and reduce the surface roughness of the overlying silver film, without increasing ohmic plasmon losses. The structures were physically and optically characterized and compared with nanostructures of single gold layer. Ultrasmooth and chemically stable trilayer nanostructures with a surface roughness <0.5 nm were obtained following a simple and reproducible fabrication process. They showed a figure of merit (FOM) value up to 69.2 RIU which is significantly higher (more than 95%) than the gold monolayer counterpart. Their potential for biosensing was demonstrated by employing the trilayer sensor for the direct and refractometric (label-free) detection of C-reactive protein (CRP) biomarker in undiluted urine achieving a Limit of Detection (LOD) in the pM order.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A label-free nanostructured plasmonic biosensor based on Blu-ray discs with integrated microfluidics for sensitive biodetection

  • López Muñoz, Gerardo Arturo
  • Estévez, M. Carmen|||0000-0003-3694-7186
  • Peláez Gutiérrez, Enelia Cristina|||0000-0002-9482-4566
  • Homs Corbera, Antoni
  • García-Hernandez, M. C.
  • Imbaud, J. I.
  • Lechuga, Laura M.|||0000-0001-5187-5358
Nanostructure-based plasmonic biosensors have quickly positioned themselves as interesting candidates for the design of portable optical biosensor platforms considering the potential benefits they can offer in integration, miniaturization, multiplexing, and real-time label-free detection. We have developed a simple integrated nanoplasmonic sensor taking advantage of the periodic nanostructured array of commercial Blu-ray discs. Sensors with two gold film thicknesses (50 and 100 nm) were fabricated and optically characterized by varying the oblique-angle of the incident light in optical reflectance measurements. Contrary to the use normal light incidence previously reported with other optical discs, we observed an enhancement in sensitivity and a narrowing of the resonant linewidths as the light incidence angle was increased, which could be related to the generation of Fano resonant modes. The new sensors achieve a figure of merit (FOM) up to 35 RIU and a competitive bulk limit of detection (LOD) of 6.3×10 RIU. These values significantly improve previously reported results obtained with normal light incidence reflectance measurements using similar structures. The sensor has been combined with versatile, simple, ease to-fabricate microfluidics. The integrated chip is only 1 cm (including a PDMS flow cell with a 50 µm height microfluidic channel fabricated with double-sided adhesive tape) and all the optical components are mounted on a 10 cm×10 cm portable prototype, illustrating its facile miniaturization, integration and potential portability. Finally, to assess the label-free biosensing capability of the new sensor, we have evaluated the presence of specific antibodies against the GTF2b protein, a tumor-associate antigen (TAA) related to colorectal cancer. We have achieved a LOD in the pM order and have assessed the feasibility of directly measuring biological samples such as human serum.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Advances in nanoplasmonic biosensors for clinical applications

  • Mauriz, Elba|||0000-0002-6459-8107
  • Dey, Priyanka|||0000-0002-7158-4491
  • Lechuga, Laura M.|||0000-0001-5187-5358
Biomarkers are unquestionable biological indicators for diagnosis and therapeutic interventions providing appropriate classification of a wide range of health disorders and risk factors. Nonetheless, the detection and quantification of biomarkers need to be tested with sufficient reliability by robust analytical methods in order to assure clinical performance in health care settings. Since the analytical performance is determined by the sensitivity and specificity of the method employed, techniques have been intensively refined in order to avoid the misinterpretation of results and undesirable bias. Although biomarkers can be detected with the existing analytical techniques, to reproducibly quantify them in decentralized settings or remote locations with the required accuracy is still a challenge. Currently, only a few point-of-care devices for biomarker evaluation are commercially available. Thus, more focused research efforts are needed to overcome these limitations in order to provide universal patient-centered care platforms. To this end, plasmonic biosensors can be conveniently used as portable diagnostic devices for attaining timely and cost-effective clinical outcomes. The development of enhanced performance based on nanoplasmonics technology opens the way for sensor miniaturization, multiplexing and point of care testing. This review covers recent advances and applications of plasmonic and nanoplasmonic biosensors intended for biomarker diagnosis in clinical practice, including cancer, cardiovascular and neurodegenerative diseases. The review specially focuses on: (i) recent progress in plasmonics development including the design of singular nanostructured surfaces, (ii) novel chemical functionalization strategies for the appropriate incorporation of bioreceptors and (iii) plasmonic applications as real operative devices in the clinical field. Future prospects in the use of nanoplasmonic sensor platforms for personalised quantification and management of biomarkers directly in body fluids will also be discussed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Advanced Evanescent-Wave Optical Biosensors for the Detection of Nucleic Acids, An Analytic Perspective

  • Huertas, César S.|||0000-0002-3100-4034
  • Calvo Lozano, Olalla|||0000-0001-5486-2237
  • Mitchell, Arnan
  • Lechuga, Laura M.|||0000-0001-5187-5358
Evanescent-wave optical biosensors have become an attractive alternative for the screening of nucleic acids in the clinical context. They possess highly sensitive transducers able to perform detection of a wide range of nucleic acid-based biomarkers without the need of any label or marker. These optical biosensor platforms are very versatile, allowing the incorporation of an almost limitless range of biorecognition probes precisely and robustly adhered to the sensor surface by covalent surface chemistry approaches. In addition, their application can be further enhanced by their combination with different processes, thanks to their integration with complex and automated microfluidic systems, facilitating the development of multiplexed and user-friendly platforms. The objective of this work is to provide a comprehensive synopsis of cutting-edge analytical strategies based on these label-free optical biosensors able to deal with the drawbacks related to DNA and RNA detection, from single point mutations assays and epigenetic alterations, to bacterial infections. Several plasmonic and silicon photonic-based biosensors are described together with their most recent applications in this area. We also identify and analyse the main challenges faced when attempting to harness this technology and how several innovative approaches introduced in the last years manage those issues, including the use of new biorecognition probes, surface functionalization approaches, signal amplification and enhancement strategies, as well as, sophisticated microfluidic solutions.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Site-Specific mRNA Cleavage for Selective and Quantitative Profiling of Alternative Splicing with Label-Free Optical Biosensors

  • Huertas, César S.|||0000-0002-3100-4034
  • Bonnal, Sophie
  • Soler Aznar, Maria|||0000-0001-7232-2277
  • Escuela, Alfonso M.
  • Valcárcel, Juan|||0000-0001-5398-3571
  • Lechuga, Laura M.|||0000-0001-5187-5358
Alternative splicing of mRNA precursors is a key process in gene regulation, contributing to the diversity of proteomes by the alternative selection of exonic sequences. Alterations in this mechanism are associated with most cancers, enhancing their proliferation and survival, and can be employed as cancer biomarkers. Label-free optical biosensors are ideal tools for the highly sensitive and label-free analysis of nucleic acids. However, their application for alternative splicing analysis has been hampered due to the formation of complex and intricate long-range base-pairing interactions which make the direct detection in mRNA isoforms difficult. To solve this bottleneck, we introduce a methodology for the generation of length-controlled RNA fragments from purified total RNA, which can be easily detected by the biosensor. The methodology seizes RNase H enzyme activity to degrade the upstream and downstream RNA segments flanking the target sequence upon hybridization to specific DNA oligos. It allows the fast and direct monitoring of Fas gene alternative splicing in real time, employing a surface plasmon resonance biosensor. We demonstrate the selective and specific detection of mRNA fragments in the pM-nM concentration range, reducing quantification errors and showing 81% accuracy when compared to RT-qPCR. The site-specific cleavage outperformed random RNA hydrolysis by increasing the detection accuracy by 20%, making this methodology particularly appropriate for label-free quantification of alternative splicing events in complex samples.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Optical nanogap antennas as plasmonic biosensors for the detection of miRNA biomarkers

  • Portela Otaño, Alejandro|||0000-0003-0868-346X
  • Calvo Lozano, Olalla|||0000-0001-5486-2237
  • Estévez, M. Carmen|||0000-0003-3694-7186
  • Medina Escuela, Alfonso
  • Lechuga, Laura M.|||0000-0001-5187-5358
Nanoplasmonic biosensors based on nanogap antenna structures usually demand complex and expensive fabrication processes in order to achieve a good performance and sensitive detection. We here report the fabrication of large-area nanoplasmonic sensor chips based on nanogap antennas by employing a customized, simple and low-cost colloidal lithography process. By precisely controlling the angle for tilted e-beam metal evaporation, an elliptical mask is produced, which defines the total length of the dipole antenna nanostructures while assuring that the plasmonic response is oriented in the same direction along the sensor chip. Large-area sensor chips of nanogap antennas formed by pairs of gold nanodisks separated by gaps with an average size of 11.6 ± 4.7 nm are obtained. The optical characterization of the nanogap antenna structures in an attenuated total reflection (ATR) configuration shows a bulk refractive index sensitivity of 422 nm per RIU, which is in agreement with FDTD numerical simulations. The biosensing potential of the cm-sized nanostructured plasmonic sensor chips has been evaluated for the detection of miRNA-210, a relevant biomarker for lung cancer diagnosis, through a DNA/miRNA hybridization assay. A limit of detection (LOD) of 0.78 nM (5.1 ng mL) was achieved with no need of further amplification steps, demonstrating the high sensitivity of these plasmonic nanogap antennas for the direct and label-free detection of low molecular weight biomolecules such as miRNAs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Boosting cancer immunotherapies with optical biosensor nanotechnologies

  • Soler Aznar, Maria|||0000-0001-7232-2277
  • Lechuga, Laura M|||0000-0001-5187-5358
An increasing number of cancer patients have found new hope in the form of recently discovered cell immunotherapies. These novel treatments empower our own immune system to fight and eradicate the malignant tumours, even in metastatic stages. Unprecedented outcomes have been demonstrated with bioengineered cells especially modified in laboratories to trigger a highly specific and active anti-tumour function; however, a main bottleneck for the implementation of these promising therapies resides in the old-fashioned and limited techniques employed for the in vitroanalysis and study of cells during manufacturing and testing processes. Optical label-free biosensors are currently arising as promising analytical technologies for a simplified and accurate cell analysis. In particular, biosensors based on evanescent field principles enable direct, non-invasive, and real-time monitoring of biological events, showing outstanding sensitivities and excellent robustness. Furthermore, these biosensors are easily incorporated in lab-on-a-chip platforms for simple operation and implementation in clinical laboratories. In this review, the authors present and discuss the more recent research aimed to develop label-free optical biosensors for the analysis of live cells and the direct benefits offered to cell immunotherapy production allowing for its widespread implementation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Fast and accurate pneumocystis pneumonia diagnosis in human samples using a label-free plasmonic biosensor

  • Calvo Lozano, Olalla|||0000-0001-5486-2237
  • Aviñó, Ana|||0000-0003-3047-738X
  • Friaza, Vicente|||0000-0002-2900-4334
  • Medina Escuela, Alfonso
  • Huertas, César S.|||0000-0002-3100-4034
  • Calderón, Enrique J.|||0000-0002-3166-5086
  • Eritja, Ramon|||0000-0001-5383-9334
  • Lechuga, Laura M.|||0000-0001-5187-5358
Pneumocystis jirovecii is a fungus responsible for human Pneumocystis pneumonia, one of the most severe infections encountered in immunodepressed individuals. The diagnosis of Pneumocystis pneumonia continues to be challenging due to the absence of specific symptoms in infected patients. Moreover, the standard diagnostic method employed for its diagnosis involves mainly PCR-based techniques, which besides being highly specific and sensitive, require specialized personnel and equipment and are time-consuming. Our aim is to demonstrate an optical biosensor methodology based on surface plasmon resonance to perform such diagnostics in an efficient and decentralized scheme. The biosensor methodology employs poly-purine reverse-Hoogsteen hairpin probes for the detection of the mitochondrial large subunit ribosomal RNA (mtLSU rRNA) gene, related to P. jirovecii detection. The biosensor device performs a real-time and label-free identification of the mtLSU rRNA gene with excellent selectivity and reproducibility, achieving limits of detection of around 2.11 nM. A preliminary evaluation of clinical samples showed rapid, label-free and specific identification of P. jirovecii in human lung fluids such as bronchoalveolar lavages or nasopharyngeal aspirates. These results offer a door for the future deployment of a sensitive diagnostic tool for fast, direct and selective detection of Pneumocystis pneumonia disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology, Implementation and Clinical Validation

  • Calvo Lozano, Olalla|||0000-0001-5486-2237
  • Sierra, Miquel
  • Soler Aznar, Maria|||0000-0001-7232-2277
  • Estévez, M. Carmen|||0000-0003-3694-7186
  • Chiscano-Camón, Luis|||0000-0003-0037-0610
  • Ruiz-Sanmartin, Adolfo
  • Ruiz-Rodriguez, Juan Carlos|||0000-0001-7392-8617
  • Ferrer, Ricard|||0000-0002-4859-4747
  • González-López, Juanjo|||0000-0003-2419-5909
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Fernandez-Naval, Candela|||0000-0002-5584-3537
  • Bueno, Leticia
  • López-Aladid, Ruben
  • Torres, Antoni|||0000-0002-8643-2167
  • Fernández Barat, Laia|||0000-0001-7528-9636
  • Attoumani, Sarah
  • Charrel, Rémi
  • Coutard, Bruno
  • Lechuga, Laura M.|||0000-0001-5187-5358
Serological tests are essential for the control and management of COVID-19 pandemic (diagnostics and surveillance, and epidemiological and immunity studies). We introduce a direct serological biosensor assay employing proprietary technology based on plasmonics, which offers rapid (<15 min) identification and quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in clinical samples, without signal amplification. The portable plasmonic device employs a custom-designed multiantigen (RBD peptide and N protein) sensor biochip and reaches detection limits in the low ng mL -1 range employing polyclonal antibodies. It has also been implemented employing the WHO-approved anti-SARS-CoV-2 immunoglobulin standard. A clinical validation with COVID-19 positive and negative samples (n = 120) demonstrates its excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor as an accurate and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the disease management and for the evaluation of immunological status during vaccination or treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

One-step and real-time detection of microRNA-21 in human samples for lung cancer biosensing diagnosis

  • Calvo Lozano, Olalla|||0000-0001-5486-2237
  • García Aparicio, Pablo|||0000-0001-9908-9639
  • Raduly, Lajos-Zsolt|||0000-0002-3926-5423
  • Estévez, M. Carmen|||0000-0003-3694-7186
  • Berindan Neagoe, Ioana|||0000-0001-5828-1325
  • Ferracin, Manuela|||0000-0002-1595-6887
  • Lechuga, Laura M|||0000-0001-5187-5358
The rapid diagnosis of cancer, especially in its early stages, is crucial for on-time medical treatment and for increasing the patient survival rate. Lung cancer shows the highest mortality rate and the lowest 5-year survival rate due to the late diagnosis in advanced cancer stages. Providing rapid and reliable diagnostic tools is a top priority to address the problem of a delayed cancer diagnosis. We introduce a nanophotonic biosensor for the direct and real-time detection in human plasma of the microRNA-21-5p biomarker related to lung cancer. The biosensor employs a silicon photonic bimodal interferometric waveguide that provides a highly sensitive detection in a label-free format. We demonstrate a very competitive detectability for direct microRNA-21-5p biomarker assays in human plasma samples (estimated LOD: 25 pM). The diagnostic capability of our biosensor was validated by analyzing 40 clinical samples from healthy individuals and lung cancer patients, previously analyzed by reverse-transcription quantitative polymerase chain reaction (qRT-PCR). We could successfully identify and quantify the levels of microRNA in a one-step assay, without the need for DNA extraction or amplification steps. The study confirmed the significance of implementing this biosensor technique compared to the benchmarking molecular analysis and showed excellent agreement with previous results employing the traditional qRT-PCR. This work opens new possibilities for the true implementation of point-of-care biosensors that enable fast, simple, and efficient early diagnosis of cancer diseases.